- Report
- October 2024
- 194 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- March 2025
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- May 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- February 2025
- 132 Pages
Global
From €3973EUR$4,365USD£3,406GBP
€4414EUR$4,850USD£3,784GBP
- Report
- May 2024
- 136 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- April 2025
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- July 2024
- 110 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2023
- 118 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- April 2023
- 115 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- May 2023
- 97 Pages
Global
From €3500EUR$4,120USD£3,106GBP

Fondaparinux is a synthetic anticoagulant drug used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It is a member of the class of drugs known as pentasaccharides, and is used in the treatment of cardiovascular diseases. Fondaparinux is administered by subcutaneous injection and is available in both generic and branded forms. It is used in combination with other anticoagulants, such as warfarin, to reduce the risk of stroke and other cardiovascular events.
Fondaparinux is a widely used drug in the cardiovascular market, and is used to treat a variety of conditions, including atrial fibrillation, coronary artery disease, and peripheral artery disease. It is also used to prevent and treat venous thromboembolism, a condition in which blood clots form in the veins.
Fondaparinux is marketed by several pharmaceutical companies, including Sanofi, Bristol-Myers Squibb, and Pfizer. It is also available in generic form from several generic drug manufacturers. Show Less Read more